Nuvation Bio Inc.
NUVBNuvation Bio Inc. is a clinical-stage biopharmaceutical company focused on developing innovative therapies for serious diseases, particularly in the fields of oncology and rare genetic disorders. The company is dedicated to discovering and advancing novel treatments that address unmet medical needs through targeted research and development efforts.
Company News
Gary Hattersley, chief scientific officer at Nuvation Bio, exercised and sold 100,000 shares under a pre-planned trading strategy, reducing his direct stock ownership to zero while retaining 298,935 stock options.
U.S. stock futures were lower this morning, with the Nasdaq futures falling by around 0.2% on Wednesday. Shares of Intel Corporation (NASDAQ: INTC) fell sharply in today’s pre-market trading after the company outlined a new financial framework for its foundry business. After the market close on Tuesday, Intel announced a new financial reporti...
Shares of LuxUrban Hotels Inc. (NASDAQ: LUXH) fell sharply during Wednesday’s session after the company issued preliminary fourth-quarter revenue outlook below estimates. LuxUrban said it expects preliminary revenue of $28.2 million for the fourth quarter, versus market estimates of $34.199 million, according to data from Benzinga Pro. LuxUrb...
U.S. stocks were higher, with the Dow Jones index gaining around 300 points on Wednesday. Shares of Cintas Corporation (NASDAQ: CTAS) rose sharply during Wednesday’s session after the company reported better-than-expected third-quarter financial results and raised FY24 guidance. Cintas posted GAAP earnings of $3.84 per share, beating market est...
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. Barclays cut the price target for Prologis, Inc. (NYSE: PLD) from $153 to $141. Barclays analyst Anthony Powell maintained an Overweight rating. Prologis s...
